ArticleCancer medicine2020
Incidence and survival of rare cancers in the US and Europe.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Occupational and environmental risk factors for salivary gland cancer: a systematic literature review.Occupational and environmental medicine · 2026Pooled it
- Malignant Solid Pseudopapillary Neoplasm of the Pancreas: An Orthogonal Analysis.Annals of surgical oncology · 2024Pooled it
- Adenocarcinoma of the small intestine cohort: prospectively collecting real-world data to improve care and quality of life for patients with a rare cancer.Acta oncologica (Stockholm, Sweden) · 2026Article
- An international multi-centre study to develop and validate federated learning-based prognostic models for anal cancer.Nature communications · 2026Article
- Therapeutic reprogramming of natural killer cells for solid tumors: expanding frontiers into rare and ultra-rare malignancies.Frontiers in molecular biosciences · 2026Review
- The European Prospective Investigation into Cancer and Nutrition Cohort (EPIC): a gateway to rare cancer epidemiological research.ESMO rare cancers · 2025Article
- Article
- Article
- The burden of rare cancers among adults in the Canton of Geneva, Switzerland, from 2011 to 2020.Frontiers in oncology · 2025Article
- De Novo Natural Language Processing Algorithm Accurately Identifies Myxofibrosarcoma From Pathology Reports.Clinical orthopaedics and related research · 2025Article
- Extrapleural pneumonectomy for sarcoma: Outcomes of adult patients at a specialized center.Cancer reports (Hoboken, N.J.) · 2024Article
- The Significance of Systemic Inflammatory Markers in Prognosis of Head and Neck Squamous Cell Cancers.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- Intraventricular schwannomas: A case report and a literature review.Rare tumors · 2024Article
- Efficacy and safety of postoperative levothyroxine sodium tablets for improving serum thyroid hormone levels and tumor marker levels in patients with thyroid tumors.European journal of translational myology · 2023Article
- Epidemiology of rare cancers in India and South Asian countries - remembering the forgotten.The Lancet regional health. Southeast Asia · 2023Article
- Geographical and spatial disparities in the incidence and survival of rare cancers in Australia.International journal of cancer · 2023Article
- Complete prevalence and indicators of cancer cure: enhanced methods and validation in Italian population-based cancer registries.Frontiers in oncology · 2023Article
- Succinate dehydrogenase variants in paraganglioma: why are B subunit variants 'bad'?Endocrine oncology (Bristol, England) · 2023Article
- The Burden of Rare Cancers in North America.Journal of registry management · 2023Article
- Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Geographical variability of cancer burden was almost exclusively estimated for common cancers. Since rare cancers (RC) have become an area of priority for basic and clinical research and public health organizations, this paper provides, using a common methodology, a detailed comparison of incidence and survival for RC in the US and Europe. We estimated incidence and net survival of 199 malignant RC from data of 2 580 000 patients collected by 18 US-SEER and 94 European registries, diagnosed within the most recent common period 2000-2007. RC were defined according to the criterion of crude annual incidence rates <6/100 000. In total, 196 RC were classified as rare in both populations. Of these, 43 had incidence rates significantly different by at least 0.2 per 100 000:34 higher in the US and 9 higher in Europe. Five-year net survival for all RC combined significantly differed: 54% in the US and 48% in Europe. Survival for 62 RC was significantly higher in the US vs 6 higher in Europe. Differences were not concentrated in a particular cancer family, and were mostly relevant for cases diagnosed >65+ years of age. Use of standardized methods evidenced that incidence and survival rate of majority of RC were higher in the United States compared to Europe. Possible reasons for such differences, requiring further studies, include distribution of risk factors, ability to diagnose RC, different registration practices, and use of updated International Classification of Diseases for Oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.